The Reinsurer’s Share: Who Really Holds Britain’s Pension Liabilities?

Few corners of the UK capital markets have grown as quietly, or as consequentially, as pension risk transfer. Each year a fresh cohort of defined benefit schemes — many now in surplus after a decade of funding improvement — hands its liabilities to an insurer in exchange for a premium. The headline numbers are striking, the pipeline is deep, and the announcements now arrive with the regularity of corporate results. What is less well understood is that the trade does not end there.

The visible transaction moves longevity and investment risk from trustees to an insurance company. The less visible transaction, and the one that should occupy investors more than it does, moves a substantial portion of that same risk onward — to reinsurers, to specialist offshore balance sheets, and increasingly to private capital that has no retail franchise and no obvious reason to remain through a full cycle. Understanding that second transfer is the difference between owning the flow and owning the risk.

A market repriced on capacity, not demand

Demand is, for practical purposes, not the constraint. The supply of schemes seeking buyout or buy-in remains ample, and trustees with surplus funding have a clear incentive to lock in security while pricing is favourable. What disciplines the market is the capital that insurers are willing, or able, to put behind each contract. Bulk annuities are capital-hungry: longevity reserves, credit reserves and the matching adjustment all pull against returns on equity, and the constraint binds hardest on the largest transactions.

That is why competition has compressed new business margins even as volumes have climbed. The London-listed life insurers active in this market have been rewarded for demonstrating growth, but the multiple the market applies to that growth depends on how much capital intensity sits behind it. Two insurers can report similar volumes and be valued quite differently, because one is retaining the risk and the other is passing most of it through a funded reinsurance treaty. Investors have, broadly, begun to appreciate the distinction. They have not yet settled on how to price it.

The onward journey

Under a funded reinsurance arrangement, the insurer cedes both assets and liabilities to a counterparty, retains an administration and origination fee, and releases much of the capital it would otherwise have to hold. The effect on reported returns on capital is flattering, and the effect on the solvency ratio is immediate. The consequence is that the ultimate holder of a British pensioner’s longevity risk may be a Bermudian or continental reinsurer, a private capital-backed vehicle, or an entity several ownership layers removed from the scheme that started the chain.

None of this is improper, and it is not new. Reinsurance has always been part of the life market. What has changed is the scale of the cession and the character of the counterparties. When a large share of a contract’s economics sits with a firm whose capital is private and whose obligations extend decades into the future, the relevant questions become collateral quality, treaty recapture terms, and whether the counterparty has genuinely matched the duration of what it has taken on.

What the regulator is watching

The Prudential Regulation Authority has spent recent years scrutinising funded reinsurance more closely, and the supervisory tone has shifted from observation to expectation. The concerns are familiar: concentration of counterparty exposure, the enforceability of collateral arrangements in stress, and the risk that capital relief is recognised faster than the underlying risk genuinely leaves the system. The Solvency UK reforms have given insurers more flexibility over how they structure and hold capital. That flexibility is valuable, but it places a greater burden on disclosure and on the judgement of the analysts who read it.

For equity investors in London-listed insurers, the practical question is not whether risk transfer is sound in principle. It is whether the specific mix — retained risk versus ceded risk, and the quality of those to whom it is ceded — is visible enough to be valued. Annual reports now disclose more than they did, but the granularity varies, and comparisons across companies remain difficult. That opacity is not a scandal waiting to happen. It is simply a discount that the market applies until it is given reason to do otherwise.

The variables that matter in 2026

Three moving parts deserve attention. The first is gilt yields. Higher yields improve scheme funding and support pricing, but they also reshape the asset portfolios that back annuity books, and a sharp move in either direction reopens questions about duration matching that had been comfortably settled.

Second is credit. Bulk annuity reserves rest heavily on investment-grade credit, and the spread widening that accompanies any growth scare acts on both sides of the trade — reducing the appeal of the assets a scheme brings and straining the assumptions embedded in reinsurance treaties. Structures that look robust in benign conditions are precisely the ones that should be tested against a less forgiving one.

Third is the composition of new entrants. Competition from private capital-backed insurers and reinsurers has been a feature of the market and, on the whole, a healthy one. But capital that arrives in search of yield and duration is not identical to capital that arrives with a mandate to hold. When the cycle turns, willingness to renew a treaty and willingness to fund a shortfall are not the same thing.

The sober reading

The bulk annuity boom is a genuine structural development, not a fad. It converts an unfunded promise held across thousands of scheme balance sheets into a funded, regulated and, in principle, well-matched insurance obligation. For UK capital markets, that is a meaningful improvement in the architecture of retirement risk.

But investors who own the listed insurers, or the credit of the reinsurers behind them, should resist reading the volume headline as though it were free growth. The trade consumes capital at origination and redistributes it downstream. The quality of a bulk annuity book is now a function of the treaties behind it as much as the schemes in front of it — and that is where the analysis should concentrate. The longevity trade is real. The question is who is still holding it when the music stops.